COR vs. MCK, CAH, HSIC, PDCO, OMI, HLF, NUS, PETQ, HWH, and BIMI
Should you be buying Cencora stock or one of its competitors? The main competitors of Cencora include McKesson (MCK), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), Nu Skin Enterprises (NUS), PetIQ (PETQ), HWH International (HWH), and BIMI (BIMI).
Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.4%. Cencora pays out 22.3% of its earnings in the form of a dividend. McKesson pays out 11.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
In the previous week, McKesson had 25 more articles in the media than Cencora. MarketBeat recorded 38 mentions for McKesson and 13 mentions for Cencora. McKesson's average media sentiment score of 0.53 beat Cencora's score of 0.32 indicating that McKesson is being referred to more favorably in the news media.
McKesson received 214 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.16% of users gave McKesson an outperform vote while only 65.12% of users gave Cencora an outperform vote.
Cencora has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Cencora presently has a consensus target price of $233.90, indicating a potential upside of 3.24%. McKesson has a consensus target price of $571.47, indicating a potential upside of 0.33%. Given Cencora's higher possible upside, equities analysts plainly believe Cencora is more favorable than McKesson.
97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 15.8% of Cencora shares are owned by company insiders. Comparatively, 0.2% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
McKesson has a net margin of 0.97% compared to Cencora's net margin of 0.67%. Cencora's return on equity of 268.67% beat McKesson's return on equity.
Summary
McKesson beats Cencora on 14 of the 19 factors compared between the two stocks.
Get Cencora News Delivered to You Automatically
Sign up to receive the latest news and ratings for COR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
